The Trump administration has added nine pharmaceutical companies to its Most-Favored-Nation pricing program, bringing the total number of participating drugmakers to 26.
President Donald J. Trump announced the expansion on August 31, with the White House stating the program now covers 89% of the branded drug market.
The nine newly added manufacturers are Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals, and UCB.
The White House said the additions “extend price caps across a broad spectrum of critical treatment categories, spanning oncology, hemophilia, Parkinson’s disease, macular degeneration, glaucoma, and chronic dermatological conditions.”
The nine companies have collectively committed at least $19.6 billion in near-term US manufacturing investments as part of their participation in the program.
The manufacturers have also agreed to donate quantities of essential active pharmaceutical ingredients, including antibiotics, anticonvulsants, and immunosuppressants, to the Strategic Active Pharmaceutical Ingredients Reserve.
Every state Medicaid program will gain access to MFN pricing on the participating companies’ products, with the White House projecting billions of dollars in aggregate savings.
Oncology specialist BeOne Medicines secured an exemption from Section 232 pharmaceutical tariffs linked to its US manufacturing investments, with only its PD-1 inhibitor Tevimbra currently subject to the Medicaid program.
BridgeBio will expand state Medicaid access to its transthyretin amyloid cardiomyopathy drug Attruby under the GENEROUS model, and the company said it “does not expect to be subject to future pricing mandates.”
The GENEROUS framework is an industry-government negotiation structure under which manufacturers provide rebates to participating states for certain drugs.
The MFN program has faced resistance from mid-sized biotechnology firms, with 10 US biotechs forming the Midsized Biotech Alliance of America in February to challenge the policy.
The alliance’s original lineup included Alkermes, Alnylam, Ardelyx, BioMarin, Exelixis, Incyte, and Neurocrine Biosciences, who argued smaller firms are less equipped to absorb MFN pricing pressures than larger pharmaceutical companies.
The Trump administration continues to position the MFN program alongside its direct-to-consumer TrumpRx platform as the centrepiece of its broader drug affordability strategy heading into 2027.